CLINICAL_TRIALS trial_result · 2020-02-05

Clinical Trial Update: Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age [Phase 3]

Phase 3 trial evaluating VX-659/TEZ/IVA in children aged 6-11 with cystic fibrosis was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: TERMINATED | Results posted: 2020-02-05